To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

This setup has several favorable features for a positive readout: it is randomized, quadruple-blind, and placebo-controlled; the primary endpoint is clinically meaningful relapse prevention; and AdjINCAT is a validated CIDP disability measure. The primary analysis is also narrowed to Period 2, Cohort A, which appears to be the most standard and diagnostically cleaner subgroup because participants are on established Ig/PLEX therapy and meet formal EAN/PNS criteria. That should reduce noise versus a broad all-comer analysis. The randomized-withdrawal structure can make a real maintenance effect easier to detect than a pure improvement study, because relapse events are more separable from placebo. Offsetting that, this remains a Phase 2 study in a heterogeneous neurologic disease, with substantial operational complexity across washout, treatment, and a long withdrawal period. That raises dropout, missing-data, and execution risk. The endpoint is solid but still vulnerable to functional-score variability. Overall, the design quality slightly outweighs phase and execution risk, giving modestly better-than-even YES odds.

Period 1 open-label data (March 2025) were strongly positive: 1.8-point aINCAT improvement across arms, 84% responder rate in patients with ≥70% IgG reduction, and consistent improvements across I-RODS, MRC-SS, and grip strength in 73 patients. FcRn inhibition is a validated MOA in CIDP (efgartigimod approved), and the randomized withdrawal design inherently favors active treatment since placebo patients lose IgG suppression and tend to relapse. These factors support a positive Period 2 primary endpoint. However, several risks temper confidence: Cohort A is a subset of 73 patients, raising power concerns for a Phase 2b. Batoclimab's TED Phase 3 studies both failed their primary endpoints (announced today April 2, 2026), suggesting potential compound-specific limitations, though TED pathophysiology differs significantly from CIDP. Immunovant has deprioritized batoclimab in favor of IMVT-1402, reducing incentive to optimize disclosure framing. The estimated primary completion date has passed by ~91 days with no Period 2 data disclosed, which could signal complications or simply data cleaning delays. On balance, strong Period 1 signal and favorable trial design support positive results.

This is a Phase 2 randomized withdrawal trial for batoclimab in CIDP, a rare autoimmune neuropathy. The design is rigorous: patients first enter a treatment period, then responders are randomized to drug vs placebo in Period 2 to assess relapse-free status at Week 36 using the validated AdjINCAT disability scale. The endpoint is clinically meaningful—relapse defined as sustained >=1 point worsening. The trial is past primary completion (-91 days), suggesting data may be maturing. Batoclimab is an FcRn inhibitor, a proven mechanism in autoimmunity (efgartigimod approved in MG). Phase 2 CIDP trials have moderate historical success rates. However, the randomized withdrawal design introduces complexity—response criteria and cohort stratification may affect generalizability. Without disclosed prior Phase 1/2 data in CIDP, intrinsic probability is modestly above even odds but with significant uncertainty.

Batoclimab is an FcRn inhibitor with a validated mechanism in IgG-driven autoimmune diseases. This Phase 2 trial in active CIDP uses a rigorous randomized withdrawal design, a standard for CIDP efficacy assessment, with a clinically meaningful primary endpoint (relapse-free rate at 36 weeks based on adjusted INCAT). The patient population is well-defined, separating treatment-experienced and naive cohorts. Prior open-label data in CIDP suggested benefit. Key risks include the placebo response inherent in withdrawal designs, the operational complexity of a multi-cohort, quadruple-blind international study, and the typical sample size limitations of a Phase 2. The primary completion date has passed, reducing timeline uncertainty. The design and mechanism support a modestly favorable intrinsic probability.

Solid Phase 2 design: quadruple-blind, placebo-controlled RCT with 12-week induction (batoclimab 340/680mg SC weekly) followed by 24-week randomized withdrawal (Period 2), assessing relapse-free survival at Week 36 via validated AdjINCAT score (>=1-point sustained worsening). Endpoint clinically meaningful, powered for Cohort A (prior Ig/PLEX responders meeting EAN/PNS criteria), enriched active CIDP population unlikely to remit spontaneously post-washout. FcRn inhibition rationale strong: batoclimab profoundly lowers IgG (pathogenic autoantibodies in CIDP), mirroring efgartigimod's positive Ph2 CIDP results (74% vs 23% relapse-free, similar withdrawal design). Multi-cohort stratification (steroids/naive/clinical dx) de-risks heterogeneity. Operational strengths: multi-center, up to 109-week duration with LTE, experienced sponsor (IMVT). Risks moderated: 12-week washout standard but dropout risk; Ph2 sizing adequate for binary endpoint; no major prior failures in CIDP. Disclosure low-risk: public biotech, standard topline readout expected soon post-Jan 2026 completion. High likelihood primary met given biology, comps, execution.

This Phase 2 study (NCT05581199) assesses batoclimab, an FcRn inhibitor, in CIDP using a randomized withdrawal design. The primary endpoint for Cohort A is relapse-free status at Week 36, measured by the validated adjusted INCAT disability score. FcRn inhibition has a strong mechanistic rationale for IgG-mediated autoimmune conditions like CIDP, and prior data in related neuromuscular diseases supports efficacy. Critically, the primary completion date was January 1, 2026, and the current status is 'Active Not Recruiting.' With the data cutoff likely passed, results depend on the quality of the blinded data. Given the robust trial design, clear clinical endpoint, and promising mechanism of action, a positive outcome is more likely than not, though execution risks remain.

Batoclimab is an FcRn inhibitor, a validated mechanism in autoimmune neurology (efgartigimod approved in MG). CIDP is a high-unmet-need indication with established endpoints (AdjINCAT). The trial design is rigorous: quadruple-blind, placebo-controlled, with a randomized withdrawal period that tests durability—a strong efficacy signal if positive. The four cohorts stratify by background therapy, improving generalizability. Primary completion was January 2026 (91 days past), suggesting data is mature or near lock. Phase 2 in orphan indications often shows exaggerated effects; however, FcRn inhibitors have demonstrated consistent IgG reduction across diseases. The main risks are CIDP heterogeneity and placebo response in neurological trials, but the withdrawal design mitigates this. No safety signals have been disclosed publicly. Disclosure risk is elevated given completion timing. Overall, mechanistic rationale and trial structure support modestly positive expected value.

Batoclimab's efficacy in CIDP is heavily supported by the validated FcRn mechanism (proven by efgartigimod's ADHERE trial) and batoclimab's own Period 1 results, which showed an 84% response rate and strong aINCAT improvements. The Period 2 primary endpoint utilizes a randomized withdrawal design, randomizing only proven Period 1 responders to batoclimab or placebo. This strongly biases the active arm toward success, as placebo patients will predictably experience pathogenic IgG rebound and clinical relapse. Although Immunovant announced in March 2025 that it will not seek regulatory approval for batoclimab in CIDP—pivoting instead to its next-generation FcRn inhibitor IMVT-1402 to avoid batoclimab's albumin and LDL side effects—the market appears to be incorrectly conflating this strategic corporate pipeline reprioritization with an actual clinical efficacy failure. The trial finished enrollment and completed Period 2. When the data is ultimately published, the primary endpoint measuring the relapse-free proportion will almost certainly be statistically positive. The current market price near 50% deeply misprices the biological near-certainty of the withdrawal trial design.

The trial is actively recruiting participants for a Phase 2 study to assess the efficacy and safety of Batoclimab in adult participants with active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The primary endpoint is the proportion of participants who remain relapse-free at Week 36. Given that the study is in Phase 2 and has a specific, measurable primary endpoint, there's a reasonable chance of positive results. However, the confidence is not higher due to the inherent uncertainties in clinical trials, including patient population variability and the specific efficacy of Batoclimab in this context.